查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1591994

體內 CRO 市場：按類型、GLP 類型、適應症 - 2025-2030 年全球預測

In Vivo CRO Market by Type (Non-Rodent, Rodent), GLP Type (GLP Toxicology, Non-GLP), Indication - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 186 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2023年體內CRO市場規模為44.6億美元，預計2024年將達到48.7億美元，複合年成長率為9.75%，預計到2030年將達到85.6億美元。

體內受託研究機構(CRO) 專門利用活體動物模型向製藥、生物技術和相關產業提供委託研究服務。對In Vivo CRO的需求源自於其在臨床前開發中的關鍵作用，提供毒理學、藥理學、藥物代謝研究等綜合服務，幫助客戶高效完成I期檢查的進行。這些服務的應用包括藥物發現、安全性評估和監管提交支持，主要最終用戶包括製藥公司、生物技術公司和研究機構。市場成長的推動因素包括研發支出的增加、對先進醫療解決方案的需求不斷成長，以及透過必要測試獲得更準確的資料來減少動物測試的道德驅動力。主要影響因素包括轉化研究的技術進步、生物製藥管道的擴展以及 CRO 與學術機構之間的合作。最近的發展凸顯了個人化醫學研究、專門疾病模型和拓展新興市場的潛在機會。為了抓住這個機會，我們建議投資 CRISPR 和人工智慧驅動的資料分析等最尖端科技，以提高預測的準確性和效率。儘管存在成長潛力，體內 CRO 市場仍面臨嚴格的監管要求、動物福利方面的道德問題以及高昂的營運成本等挑戰。為了克服這些問題，公司應該提倡透明的道德實踐，投資替代方法來實現 3R（替代、減少、改進），並專注於自動化以簡化流程。創新領域包括開發更多與人類相關的模型，例如晶片器官，以及探索人工智慧在預測分析中的作用，以最大限度地減少資源利用率。市場呈現出以快速技術創新和監管環境為特徵的動態性質，要求相關人員保持適應性和遠見，以維持業務成長並保持競爭力。

主要市場統計
基準年[2023] 44.6億美元
預測年份 [2024] 48.7億美元
預測年份 [2030] 85.6億美元
複合年成長率（%） 9.75%

市場動態：揭示快速發展的體內 CRO 市場的關鍵市場洞察

供需的動態交互作用正在改變體內 CRO 市場。了解這些不斷變化的市場動態可以幫助企業做出明智的投資決策、策略決策並抓住新的商機。全面了解這些趨勢可以幫助企業降低政治、地理、技術、社會和經濟領域的風險，同時消費行為及其對製造成本的影響以及對採購趨勢的影響。

  • 市場促進因素
    • 由於經濟利益而增加使用外包服務
    • 增加公共和私人對藥物研究的投資
    • 對生物相似藥和藥物開發的日益關注
  • 市場限制因素
    • 與臨床測試過程相關的高成本
  • 市場機會
    • 臨床測試流程的全球化
    • 基於專利申請的製藥領域競爭狀況
  • 市場問題
    • In vivo CRO品管問題

波特五力：駕馭體內 CRO 市場的策略工具

波特的五力框架是了解市場競爭格局的重要工具。波特的五力框架描述了評估公司競爭和探索策略機會的清晰方法。該框架可幫助公司評估市場動態並確定新業務的盈利。這些見解使公司能夠利用自己的優勢，解決弱點並避免潛在的挑戰，從而確保更強大的市場地位。

PESTLE分析：了解 In Vivo CRO 市場的外部影響

外部宏觀環境因素在塑造 In Vivo CRO 市場的績效動態發揮著至關重要的作用。對政治、經濟、社會、技術、法律和環境因素的分析提供了應對這些影響所需的資訊。透過調查 PESTLE 因素，公司可以更了解潛在的風險和機會。這種分析可以幫助企業預測法規、消費者偏好和經濟趨勢的變化，並為他們做出積極主動的決策做好準備。

市場佔有率分析：了解體內 CRO 市場的競爭格局

對體內 CRO 市場的詳細市場佔有率分析可以對供應商績效進行全面評估。公司可以透過比較收益、客戶群和成長率等關鍵指標來揭示其競爭地位。該分析揭示了市場集中、細分和整合的趨勢，為供應商提供了製定策略決策所需的洞察力，使他們能夠在日益激烈的競爭中佔有一席之地。

FPNV 定位矩陣：體內 CRO 市場供應商績效評估

FPNV定位矩陣是評估In Vivo CRO市場供應商的重要工具。此矩陣允許業務組織根據商務策略和產品滿意度評估供應商，從而做出與其目標相符的明智決策。這四個象限使您能夠清晰、準確地分類供應商，並確定最能滿足您的策略目標的合作夥伴和解決方案。

策略分析與建議：繪製體內 CRO 市場的成功之路

對於旨在加強其在全球市場的影響力的公司來說，體內 CRO 市場的策略分析至關重要。透過審查關鍵資源、能力和績效指標，公司可以識別成長機會並努力改進。這種方法使您能夠克服競爭環境中的挑戰，利用新的商機並取得長期成功。

該報告對涵蓋關鍵焦點細分市場的市場進行了全面分析。

1.市場滲透率：對當前市場環境的詳細審查，主要企業的廣泛資料，評估他們在市場中的影響力和整體影響力。

2. 市場開拓：辨識新興市場的成長機會，評估現有細分市場的擴張潛力，並提供未來成長的策略藍圖。

3. 市場多元化：分析近期產品發布、開拓地區、關鍵產業進展、塑造市場的策略投資。

4. 競爭評估與情報：徹底分析競爭格局，檢驗市場佔有率、業務策略、產品系列、認證、監管核准、專利趨勢、主要企業的技術進步等。

5. 產品開發與創新：重點在於有望推動未來市場成長的最尖端科技、研發活動和產品創新。

我們也回答重要問題，以幫助相關人員做出明智的決策。

1.目前的市場規模和未來的成長預測是多少？

2. 哪些產品和地區提供最佳投資機會？

3.塑造市場的關鍵技術趨勢和監管影響是什麼？

4.主要廠商的市場佔有率和競爭地位如何？

5. 推動供應商市場進入和退出策略的收益來源和策略機會是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 由於經濟利益而增加使用外包服務
      • 增加公共和私營部門對藥物研究的投資
      • 生物相似藥和藥品的開發日益受到關注
    • 抑制因素
      • 與臨床測試過程相關的高成本
    • 機會
      • 臨床測試流程的全球化
      • 醫藥領域的專利申請競爭格局
    • 任務
      • 體內CRO的品管問題
  • 市場區隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治
    • 經濟
    • 社會
    • 科技
    • 法律
    • 環境

第6章體內 CRO 市場：依類型

  • 介紹
  • 不囓齒動物
  • 囓齒動物
    • 老鼠
    • 鼠

第 7 章 體內 CRO 市場：依 GLP 類型

  • 介紹
  • GLP
    • 公司內部
    • 外包
  • 非GLP
    • 公司內部
    • 外包

第8章體內 CRO 市場：依適應症分類

  • 介紹
  • 自體免疫/發炎疾病
    • 大腸激躁症
    • 多發性硬化症
    • 骨關節炎
    • 類風濕性關節炎
  • 血癌
  • 中樞神經系統狀況
    • 肌萎縮側索硬化症
    • 癲癇
    • 亨丁頓舞蹈症
    • 肌肉再生
    • 帕金森氏症
    • 中風
    • 腦外傷
  • 糖尿病
  • 肥胖
  • 腫瘤學
  • 疼痛管理
    • 急性疼痛
    • 慢性疼痛
  • 固態腫瘤
    • 患者來源的異種移植物
    • 類似型號
    • 異種移植

第9章美洲體內CRO市場

  • 介紹
  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第10章亞太體內CRO市場

  • 介紹
  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第11章 歐洲、中東和非洲體內CRO市場

  • 介紹
  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第12章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023
  • 競爭情境分析
  • 戰略分析和建議

公司名單

  • Charles River Laboratories
  • Crown Bioscience, Inc.
  • Eurofins Scientific SE
  • Evotec SE
  • ICON Plc
  • Labcorp Drug Development
  • Medpace, Inc.
  • MI Bioresearch, Inc.
  • Parexel International Corporation
  • Pharmacology Discovery Services
  • PPD Inc.
  • Syneos Health
  • Syngene International Limited
  • Taconic Biosciences, Inc.
  • WuXi AppTec, Inc.
Product Code: MRR-0D217D5AEEAC

The In Vivo CRO Market was valued at USD 4.46 billion in 2023, expected to reach USD 4.87 billion in 2024, and is projected to grow at a CAGR of 9.75%, to USD 8.56 billion by 2030.

In Vivo Contract Research Organizations (CROs) specialize in providing outsourced research services that involve live animal models to pharmaceutical, biotechnology, and related industries. The necessity of in vivo CROs stems from their critical role in preclinical development, enabling clients to efficiently conduct Phase I trials by offering comprehensive services such as toxicology, pharmacology, and drug metabolism studies. The application of these services spans drug discovery, safety evaluation, and regulatory submission support, with prominent end-users including pharmaceutical companies, biotechnology firms, and research institutions. Market growth is fueled by increased R&D spending, rising demand for advanced healthcare solutions, and the ethical push for reducing animal testing through more precise data from necessary studies. Key influencing factors include technological advancements in translational research, growing biopharmaceutical pipelines, and collaborations between CROs and academia. Recent trends highlight potential opportunities in personalized medicine research, specialized disease models, and expansion into emerging markets. Recommendations for capturing these opportunities involve investing in cutting-edge technologies such as CRISPR and AI-driven data analytics, which enhance predictive accuracy and efficiency. Despite its growth potential, the in vivo CRO market faces challenges like stringent regulatory demands, ethical concerns on animal welfare, and high operational costs. To overcome these, companies should advocate for transparent ethical practices, invest in alternative methods to achieve the 3Rs (Replacement, Reduction, Refinement), and focus on automation to streamline processes. Innovation areas include developing more human-relevant models like organ-on-chips and exploring AI's role in predictive analytics to minimize resource utilization. The market exhibits a dynamic nature characterized by rapid technological changes and regulatory landscapes, necessitating stakeholders to remain adaptive and forward-thinking to sustain business growth and remain competitive.

KEY MARKET STATISTICS
Base Year [2023] USD 4.46 billion
Estimated Year [2024] USD 4.87 billion
Forecast Year [2030] USD 8.56 billion
CAGR (%) 9.75%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving In Vivo CRO Market

The In Vivo CRO Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Increasing usage of outsourcing services due to economic benefits
    • Growing investments in the pharmaceutical research by public and private sectors
    • Rising focus on the development of biosimilar medicines and drugs
  • Market Restraints
    • High cost associated with the clinical trial processes
  • Market Opportunities
    • Globalization of clinical trial processes
    • Competitive landscape in the pharmaceutical sector with patent applications
  • Market Challenges
    • Issues related to quality control in In vivo CROs

Porter's Five Forces: A Strategic Tool for Navigating the In Vivo CRO Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the In Vivo CRO Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the In Vivo CRO Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the In Vivo CRO Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the In Vivo CRO Market

A detailed market share analysis in the In Vivo CRO Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the In Vivo CRO Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the In Vivo CRO Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the In Vivo CRO Market

A strategic analysis of the In Vivo CRO Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the In Vivo CRO Market, highlighting leading vendors and their innovative profiles. These include Charles River Laboratories, Crown Bioscience, Inc., Eurofins Scientific SE, Evotec SE, ICON Plc, Labcorp Drug Development, Medpace, Inc., MI Bioresearch, Inc., Parexel International Corporation, Pharmacology Discovery Services, PPD Inc., Syneos Health, Syngene International Limited, Taconic Biosciences, Inc., and WuXi AppTec, Inc..

Market Segmentation & Coverage

This research report categorizes the In Vivo CRO Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Type, market is studied across Non-Rodent and Rodent. The Rodent is further studied across Mice and Rats.
  • Based on GLP Type, market is studied across GLP Toxicology and Non-GLP. The GLP Toxicology is further studied across In House and Outsourcing. The Non-GLP is further studied across In House and Outsourcing.
  • Based on Indication, market is studied across Autoimmune/inflammation conditions, Blood Cancer, CNS conditions, Diabetes, Obesity, Oncology, Pain management, and Solid Tumor. The Autoimmune/inflammation conditions is further studied across Irritable Bowel Syndrome, Multiple Sclerosis, Osteoarthritis, and Rheumatoid Arthritis. The CNS conditions is further studied across ALS, Epilepsy, Huntington's Disease, Muscle Regeneration, Parkinson's Disease, Stroke, and Traumatic Brain Injury. The Pain management is further studied across Acute Pain and Chronic Pain. The Solid Tumor is further studied across Patient-derived Xenograft, Syngeneic Model, and Xenograft.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Increasing usage of outsourcing services due to economic benefits
      • 5.1.1.2. Growing investments in the pharmaceutical research by public and private sectors
      • 5.1.1.3. Rising focus on the development of biosimilar medicines and drugs
    • 5.1.2. Restraints
      • 5.1.2.1. High cost associated with the clinical trial processes
    • 5.1.3. Opportunities
      • 5.1.3.1. Globalization of clinical trial processes
      • 5.1.3.2. Competitive landscape in the pharmaceutical sector with patent applications
    • 5.1.4. Challenges
      • 5.1.4.1. Issues related to quality control in In vivo CROs
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. In Vivo CRO Market, by Type

  • 6.1. Introduction
  • 6.2. Non-Rodent
  • 6.3. Rodent
    • 6.3.1. Mice
    • 6.3.2. Rats

7. In Vivo CRO Market, by GLP Type

  • 7.1. Introduction
  • 7.2. GLP Toxicology
    • 7.2.1. In House
    • 7.2.2. Outsourcing
  • 7.3. Non-GLP
    • 7.3.1. In House
    • 7.3.2. Outsourcing

8. In Vivo CRO Market, by Indication

  • 8.1. Introduction
  • 8.2. Autoimmune/inflammation conditions
    • 8.2.1. Irritable Bowel Syndrome
    • 8.2.2. Multiple Sclerosis
    • 8.2.3. Osteoarthritis
    • 8.2.4. Rheumatoid Arthritis
  • 8.3. Blood Cancer
  • 8.4. CNS conditions
    • 8.4.1. ALS
    • 8.4.2. Epilepsy
    • 8.4.3. Huntington's Disease
    • 8.4.4. Muscle Regeneration
    • 8.4.5. Parkinson's Disease
    • 8.4.6. Stroke
    • 8.4.7. Traumatic Brain Injury
  • 8.5. Diabetes
  • 8.6. Obesity
  • 8.7. Oncology
  • 8.8. Pain management
    • 8.8.1. Acute Pain
    • 8.8.2. Chronic Pain
  • 8.9. Solid Tumor
    • 8.9.1. Patient-derived Xenograft
    • 8.9.2. Syngeneic Model
    • 8.9.3. Xenograft

9. Americas In Vivo CRO Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States

10. Asia-Pacific In Vivo CRO Market

  • 10.1. Introduction
  • 10.2. Australia
  • 10.3. China
  • 10.4. India
  • 10.5. Indonesia
  • 10.6. Japan
  • 10.7. Malaysia
  • 10.8. Philippines
  • 10.9. Singapore
  • 10.10. South Korea
  • 10.11. Taiwan
  • 10.12. Thailand
  • 10.13. Vietnam

11. Europe, Middle East & Africa In Vivo CRO Market

  • 11.1. Introduction
  • 11.2. Denmark
  • 11.3. Egypt
  • 11.4. Finland
  • 11.5. France
  • 11.6. Germany
  • 11.7. Israel
  • 11.8. Italy
  • 11.9. Netherlands
  • 11.10. Nigeria
  • 11.11. Norway
  • 11.12. Poland
  • 11.13. Qatar
  • 11.14. Russia
  • 11.15. Saudi Arabia
  • 11.16. South Africa
  • 11.17. Spain
  • 11.18. Sweden
  • 11.19. Switzerland
  • 11.20. Turkey
  • 11.21. United Arab Emirates
  • 11.22. United Kingdom

12. Competitive Landscape

  • 12.1. Market Share Analysis, 2023
  • 12.2. FPNV Positioning Matrix, 2023
  • 12.3. Competitive Scenario Analysis
  • 12.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Charles River Laboratories
  • 2. Crown Bioscience, Inc.
  • 3. Eurofins Scientific SE
  • 4. Evotec SE
  • 5. ICON Plc
  • 6. Labcorp Drug Development
  • 7. Medpace, Inc.
  • 8. MI Bioresearch, Inc.
  • 9. Parexel International Corporation
  • 10. Pharmacology Discovery Services
  • 11. PPD Inc.
  • 12. Syneos Health
  • 13. Syngene International Limited
  • 14. Taconic Biosciences, Inc.
  • 15. WuXi AppTec, Inc.

LIST OF FIGURES

  • FIGURE 1. IN VIVO CRO MARKET RESEARCH PROCESS
  • FIGURE 2. IN VIVO CRO MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL IN VIVO CRO MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL IN VIVO CRO MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL IN VIVO CRO MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL IN VIVO CRO MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL IN VIVO CRO MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL IN VIVO CRO MARKET SIZE, BY GLP TYPE, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL IN VIVO CRO MARKET SIZE, BY GLP TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL IN VIVO CRO MARKET SIZE, BY INDICATION, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL IN VIVO CRO MARKET SIZE, BY INDICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. AMERICAS IN VIVO CRO MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 13. AMERICAS IN VIVO CRO MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. UNITED STATES IN VIVO CRO MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 15. UNITED STATES IN VIVO CRO MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. ASIA-PACIFIC IN VIVO CRO MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. ASIA-PACIFIC IN VIVO CRO MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA IN VIVO CRO MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. EUROPE, MIDDLE EAST & AFRICA IN VIVO CRO MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. IN VIVO CRO MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 21. IN VIVO CRO MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. IN VIVO CRO MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL IN VIVO CRO MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL IN VIVO CRO MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL IN VIVO CRO MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. IN VIVO CRO MARKET DYNAMICS
  • TABLE 7. GLOBAL IN VIVO CRO MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL IN VIVO CRO MARKET SIZE, BY NON-RODENT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL IN VIVO CRO MARKET SIZE, BY RODENT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL IN VIVO CRO MARKET SIZE, BY MICE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL IN VIVO CRO MARKET SIZE, BY RATS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL IN VIVO CRO MARKET SIZE, BY RODENT, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL IN VIVO CRO MARKET SIZE, BY GLP TYPE, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL IN VIVO CRO MARKET SIZE, BY GLP TOXICOLOGY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL IN VIVO CRO MARKET SIZE, BY IN HOUSE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL IN VIVO CRO MARKET SIZE, BY OUTSOURCING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL IN VIVO CRO MARKET SIZE, BY GLP TOXICOLOGY, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL IN VIVO CRO MARKET SIZE, BY NON-GLP, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL IN VIVO CRO MARKET SIZE, BY IN HOUSE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL IN VIVO CRO MARKET SIZE, BY OUTSOURCING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL IN VIVO CRO MARKET SIZE, BY NON-GLP, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL IN VIVO CRO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL IN VIVO CRO MARKET SIZE, BY AUTOIMMUNE/INFLAMMATION CONDITIONS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL IN VIVO CRO MARKET SIZE, BY IRRITABLE BOWEL SYNDROME, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL IN VIVO CRO MARKET SIZE, BY MULTIPLE SCLEROSIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 26. GLOBAL IN VIVO CRO MARKET SIZE, BY OSTEOARTHRITIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 27. GLOBAL IN VIVO CRO MARKET SIZE, BY RHEUMATOID ARTHRITIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 28. GLOBAL IN VIVO CRO MARKET SIZE, BY AUTOIMMUNE/INFLAMMATION CONDITIONS, 2018-2030 (USD MILLION)
  • TABLE 29. GLOBAL IN VIVO CRO MARKET SIZE, BY BLOOD CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 30. GLOBAL IN VIVO CRO MARKET SIZE, BY CNS CONDITIONS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 31. GLOBAL IN VIVO CRO MARKET SIZE, BY ALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 32. GLOBAL IN VIVO CRO MARKET SIZE, BY EPILEPSY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 33. GLOBAL IN VIVO CRO MARKET SIZE, BY HUNTINGTON'S DISEASE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 34. GLOBAL IN VIVO CRO MARKET SIZE, BY MUSCLE REGENERATION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 35. GLOBAL IN VIVO CRO MARKET SIZE, BY PARKINSON'S DISEASE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 36. GLOBAL IN VIVO CRO MARKET SIZE, BY STROKE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 37. GLOBAL IN VIVO CRO MARKET SIZE, BY TRAUMATIC BRAIN INJURY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 38. GLOBAL IN VIVO CRO MARKET SIZE, BY CNS CONDITIONS, 2018-2030 (USD MILLION)
  • TABLE 39. GLOBAL IN VIVO CRO MARKET SIZE, BY DIABETES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 40. GLOBAL IN VIVO CRO MARKET SIZE, BY OBESITY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 41. GLOBAL IN VIVO CRO MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 42. GLOBAL IN VIVO CRO MARKET SIZE, BY PAIN MANAGEMENT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 43. GLOBAL IN VIVO CRO MARKET SIZE, BY ACUTE PAIN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 44. GLOBAL IN VIVO CRO MARKET SIZE, BY CHRONIC PAIN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 45. GLOBAL IN VIVO CRO MARKET SIZE, BY PAIN MANAGEMENT, 2018-2030 (USD MILLION)
  • TABLE 46. GLOBAL IN VIVO CRO MARKET SIZE, BY SOLID TUMOR, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 47. GLOBAL IN VIVO CRO MARKET SIZE, BY PATIENT-DERIVED XENOGRAFT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 48. GLOBAL IN VIVO CRO MARKET SIZE, BY SYNGENEIC MODEL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 49. GLOBAL IN VIVO CRO MARKET SIZE, BY XENOGRAFT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 50. GLOBAL IN VIVO CRO MARKET SIZE, BY SOLID TUMOR, 2018-2030 (USD MILLION)
  • TABLE 51. AMERICAS IN VIVO CRO MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 52. AMERICAS IN VIVO CRO MARKET SIZE, BY RODENT, 2018-2030 (USD MILLION)
  • TABLE 53. AMERICAS IN VIVO CRO MARKET SIZE, BY GLP TYPE, 2018-2030 (USD MILLION)
  • TABLE 54. AMERICAS IN VIVO CRO MARKET SIZE, BY GLP TOXICOLOGY, 2018-2030 (USD MILLION)
  • TABLE 55. AMERICAS IN VIVO CRO MARKET SIZE, BY NON-GLP, 2018-2030 (USD MILLION)
  • TABLE 56. AMERICAS IN VIVO CRO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 57. AMERICAS IN VIVO CRO MARKET SIZE, BY AUTOIMMUNE/INFLAMMATION CONDITIONS, 2018-2030 (USD MILLION)
  • TABLE 58. AMERICAS IN VIVO CRO MARKET SIZE, BY CNS CONDITIONS, 2018-2030 (USD MILLION)
  • TABLE 59. AMERICAS IN VIVO CRO MARKET SIZE, BY PAIN MANAGEMENT, 2018-2030 (USD MILLION)
  • TABLE 60. AMERICAS IN VIVO CRO MARKET SIZE, BY SOLID TUMOR, 2018-2030 (USD MILLION)
  • TABLE 61. AMERICAS IN VIVO CRO MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 62. ARGENTINA IN VIVO CRO MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 63. ARGENTINA IN VIVO CRO MARKET SIZE, BY RODENT, 2018-2030 (USD MILLION)
  • TABLE 64. ARGENTINA IN VIVO CRO MARKET SIZE, BY GLP TYPE, 2018-2030 (USD MILLION)
  • TABLE 65. ARGENTINA IN VIVO CRO MARKET SIZE, BY GLP TOXICOLOGY, 2018-2030 (USD MILLION)
  • TABLE 66. ARGENTINA IN VIVO CRO MARKET SIZE, BY NON-GLP, 2018-2030 (USD MILLION)
  • TABLE 67. ARGENTINA IN VIVO CRO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 68. ARGENTINA IN VIVO CRO MARKET SIZE, BY AUTOIMMUNE/INFLAMMATION CONDITIONS, 2018-2030 (USD MILLION)
  • TABLE 69. ARGENTINA IN VIVO CRO MARKET SIZE, BY CNS CONDITIONS, 2018-2030 (USD MILLION)
  • TABLE 70. ARGENTINA IN VIVO CRO MARKET SIZE, BY PAIN MANAGEMENT, 2018-2030 (USD MILLION)
  • TABLE 71. ARGENTINA IN VIVO CRO MARKET SIZE, BY SOLID TUMOR, 2018-2030 (USD MILLION)
  • TABLE 72. BRAZIL IN VIVO CRO MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 73. BRAZIL IN VIVO CRO MARKET SIZE, BY RODENT, 2018-2030 (USD MILLION)
  • TABLE 74. BRAZIL IN VIVO CRO MARKET SIZE, BY GLP TYPE, 2018-2030 (USD MILLION)
  • TABLE 75. BRAZIL IN VIVO CRO MARKET SIZE, BY GLP TOXICOLOGY, 2018-2030 (USD MILLION)
  • TABLE 76. BRAZIL IN VIVO CRO MARKET SIZE, BY NON-GLP, 2018-2030 (USD MILLION)
  • TABLE 77. BRAZIL IN VIVO CRO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 78. BRAZIL IN VIVO CRO MARKET SIZE, BY AUTOIMMUNE/INFLAMMATION CONDITIONS, 2018-2030 (USD MILLION)
  • TABLE 79. BRAZIL IN VIVO CRO MARKET SIZE, BY CNS CONDITIONS, 2018-2030 (USD MILLION)
  • TABLE 80. BRAZIL IN VIVO CRO MARKET SIZE, BY PAIN MANAGEMENT, 2018-2030 (USD MILLION)
  • TABLE 81. BRAZIL IN VIVO CRO MARKET SIZE, BY SOLID TUMOR, 2018-2030 (USD MILLION)
  • TABLE 82. CANADA IN VIVO CRO MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 83. CANADA IN VIVO CRO MARKET SIZE, BY RODENT, 2018-2030 (USD MILLION)
  • TABLE 84. CANADA IN VIVO CRO MARKET SIZE, BY GLP TYPE, 2018-2030 (USD MILLION)
  • TABLE 85. CANADA IN VIVO CRO MARKET SIZE, BY GLP TOXICOLOGY, 2018-2030 (USD MILLION)
  • TABLE 86. CANADA IN VIVO CRO MARKET SIZE, BY NON-GLP, 2018-2030 (USD MILLION)
  • TABLE 87. CANADA IN VIVO CRO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 88. CANADA IN VIVO CRO MARKET SIZE, BY AUTOIMMUNE/INFLAMMATION CONDITIONS, 2018-2030 (USD MILLION)
  • TABLE 89. CANADA IN VIVO CRO MARKET SIZE, BY CNS CONDITIONS, 2018-2030 (USD MILLION)
  • TABLE 90. CANADA IN VIVO CRO MARKET SIZE, BY PAIN MANAGEMENT, 2018-2030 (USD MILLION)
  • TABLE 91. CANADA IN VIVO CRO MARKET SIZE, BY SOLID TUMOR, 2018-2030 (USD MILLION)
  • TABLE 92. MEXICO IN VIVO CRO MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 93. MEXICO IN VIVO CRO MARKET SIZE, BY RODENT, 2018-2030 (USD MILLION)
  • TABLE 94. MEXICO IN VIVO CRO MARKET SIZE, BY GLP TYPE, 2018-2030 (USD MILLION)
  • TABLE 95. MEXICO IN VIVO CRO MARKET SIZE, BY GLP TOXICOLOGY, 2018-2030 (USD MILLION)
  • TABLE 96. MEXICO IN VIVO CRO MARKET SIZE, BY NON-GLP, 2018-2030 (USD MILLION)
  • TABLE 97. MEXICO IN VIVO CRO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 98. MEXICO IN VIVO CRO MARKET SIZE, BY AUTOIMMUNE/INFLAMMATION CONDITIONS, 2018-2030 (USD MILLION)
  • TABLE 99. MEXICO IN VIVO CRO MARKET SIZE, BY CNS CONDITIONS, 2018-2030 (USD MILLION)
  • TABLE 100. MEXICO IN VIVO CRO MARKET SIZE, BY PAIN MANAGEMENT, 2018-2030 (USD MILLION)
  • TABLE 101. MEXICO IN VIVO CRO MARKET SIZE, BY SOLID TUMOR, 2018-2030 (USD MILLION)
  • TABLE 102. UNITED STATES IN VIVO CRO MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 103. UNITED STATES IN VIVO CRO MARKET SIZE, BY RODENT, 2018-2030 (USD MILLION)
  • TABLE 104. UNITED STATES IN VIVO CRO MARKET SIZE, BY GLP TYPE, 2018-2030 (USD MILLION)
  • TABLE 105. UNITED STATES IN VIVO CRO MARKET SIZE, BY GLP TOXICOLOGY, 2018-2030 (USD MILLION)
  • TABLE 106. UNITED STATES IN VIVO CRO MARKET SIZE, BY NON-GLP, 2018-2030 (USD MILLION)
  • TABLE 107. UNITED STATES IN VIVO CRO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 108. UNITED STATES IN VIVO CRO MARKET SIZE, BY AUTOIMMUNE/INFLAMMATION CONDITIONS, 2018-2030 (USD MILLION)
  • TABLE 109. UNITED STATES IN VIVO CRO MARKET SIZE, BY CNS CONDITIONS, 2018-2030 (USD MILLION)
  • TABLE 110. UNITED STATES IN VIVO CRO MARKET SIZE, BY PAIN MANAGEMENT, 2018-2030 (USD MILLION)
  • TABLE 111. UNITED STATES IN VIVO CRO MARKET SIZE, BY SOLID TUMOR, 2018-2030 (USD MILLION)
  • TABLE 112. UNITED STATES IN VIVO CRO MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 113. ASIA-PACIFIC IN VIVO CRO MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 114. ASIA-PACIFIC IN VIVO CRO MARKET SIZE, BY RODENT, 2018-2030 (USD MILLION)
  • TABLE 115. ASIA-PACIFIC IN VIVO CRO MARKET SIZE, BY GLP TYPE, 2018-2030 (USD MILLION)
  • TABLE 116. ASIA-PACIFIC IN VIVO CRO MARKET SIZE, BY GLP TOXICOLOGY, 2018-2030 (USD MILLION)
  • TABLE 117. ASIA-PACIFIC IN VIVO CRO MARKET SIZE, BY NON-GLP, 2018-2030 (USD MILLION)
  • TABLE 118. ASIA-PACIFIC IN VIVO CRO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 119. ASIA-PACIFIC IN VIVO CRO MARKET SIZE, BY AUTOIMMUNE/INFLAMMATION CONDITIONS, 2018-2030 (USD MILLION)
  • TABLE 120. ASIA-PACIFIC IN VIVO CRO MARKET SIZE, BY CNS CONDITIONS, 2018-2030 (USD MILLION)
  • TABLE 121. ASIA-PACIFIC IN VIVO CRO MARKET SIZE, BY PAIN MANAGEMENT, 2018-2030 (USD MILLION)
  • TABLE 122. ASIA-PACIFIC IN VIVO CRO MARKET SIZE, BY SOLID TUMOR, 2018-2030 (USD MILLION)
  • TABLE 123. ASIA-PACIFIC IN VIVO CRO MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 124. AUSTRALIA IN VIVO CRO MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 125. AUSTRALIA IN VIVO CRO MARKET SIZE, BY RODENT, 2018-2030 (USD MILLION)
  • TABLE 126. AUSTRALIA IN VIVO CRO MARKET SIZE, BY GLP TYPE, 2018-2030 (USD MILLION)
  • TABLE 127. AUSTRALIA IN VIVO CRO MARKET SIZE, BY GLP TOXICOLOGY, 2018-2030 (USD MILLION)
  • TABLE 128. AUSTRALIA IN VIVO CRO MARKET SIZE, BY NON-GLP, 2018-2030 (USD MILLION)
  • TABLE 129. AUSTRALIA IN VIVO CRO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 130. AUSTRALIA IN VIVO CRO MARKET SIZE, BY AUTOIMMUNE/INFLAMMATION CONDITIONS, 2018-2030 (USD MILLION)
  • TABLE 131. AUSTRALIA IN VIVO CRO MARKET SIZE, BY CNS CONDITIONS, 2018-2030 (USD MILLION)
  • TABLE 132. AUSTRALIA IN VIVO CRO MARKET SIZE, BY PAIN MANAGEMENT, 2018-2030 (USD MILLION)
  • TABLE 133. AUSTRALIA IN VIVO CRO MARKET SIZE, BY SOLID TUMOR, 2018-2030 (USD MILLION)
  • TABLE 134. CHINA IN VIVO CRO MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 135. CHINA IN VIVO CRO MARKET SIZE, BY RODENT, 2018-2030 (USD MILLION)
  • TABLE 136. CHINA IN VIVO CRO MARKET SIZE, BY GLP TYPE, 2018-2030 (USD MILLION)
  • TABLE 137. CHINA IN VIVO CRO MARKET SIZE, BY GLP TOXICOLOGY, 2018-2030 (USD MILLION)
  • TABLE 138. CHINA IN VIVO CRO MARKET SIZE, BY NON-GLP, 2018-2030 (USD MILLION)
  • TABLE 139. CHINA IN VIVO CRO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 140. CHINA IN VIVO CRO MARKET SIZE, BY AUTOIMMUNE/INFLAMMATION CONDITIONS, 2018-2030 (USD MILLION)
  • TABLE 141. CHINA IN VIVO CRO MARKET SIZE, BY CNS CONDITIONS, 2018-2030 (USD MILLION)
  • TABLE 142. CHINA IN VIVO CRO MARKET SIZE, BY PAIN MANAGEMENT, 2018-2030 (USD MILLION)
  • TABLE 143. CHINA IN VIVO CRO MARKET SIZE, BY SOLID TUMOR, 2018-2030 (USD MILLION)
  • TABLE 144. INDIA IN VIVO CRO MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 145. INDIA IN VIVO CRO MARKET SIZE, BY RODENT, 2018-2030 (USD MILLION)
  • TABLE 146. INDIA IN VIVO CRO MARKET SIZE, BY GLP TYPE, 2018-2030 (USD MILLION)
  • TABLE 147. INDIA IN VIVO CRO MARKET SIZE, BY GLP TOXICOLOGY, 2018-2030 (USD MILLION)
  • TABLE 148. INDIA IN VIVO CRO MARKET SIZE, BY NON-GLP, 2018-2030 (USD MILLION)
  • TABLE 149. INDIA IN VIVO CRO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 150. INDIA IN VIVO CRO MARKET SIZE, BY AUTOIMMUNE/INFLAMMATION CONDITIONS, 2018-2030 (USD MILLION)
  • TABLE 151. INDIA IN VIVO CRO MARKET SIZE, BY CNS CONDITIONS, 2018-2030 (USD MILLION)
  • TABLE 152. INDIA IN VIVO CRO MARKET SIZE, BY PAIN MANAGEMENT, 2018-2030 (USD MILLION)
  • TABLE 153. INDIA IN VIVO CRO MARKET SIZE, BY SOLID TUMOR, 2018-2030 (USD MILLION)
  • TABLE 154. INDONESIA IN VIVO CRO MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 155. INDONESIA IN VIVO CRO MARKET SIZE, BY RODENT, 2018-2030 (USD MILLION)
  • TABLE 156. INDONESIA IN VIVO CRO MARKET SIZE, BY GLP TYPE, 2018-2030 (USD MILLION)
  • TABLE 157. INDONESIA IN VIVO CRO MARKET SIZE, BY GLP TOXICOLOGY, 2018-2030 (USD MILLION)
  • TABLE 158. INDONESIA IN VIVO CRO MARKET SIZE, BY NON-GLP, 2018-2030 (USD MILLION)
  • TABLE 159. INDONESIA IN VIVO CRO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 160. INDONESIA IN VIVO CRO MARKET SIZE, BY AUTOIMMUNE/INFLAMMATION CONDITIONS, 2018-2030 (USD MILLION)
  • TABLE 161. INDONESIA IN VIVO CRO MARKET SIZE, BY CNS CONDITIONS, 2018-2030 (USD MILLION)
  • TABLE 162. INDONESIA IN VIVO CRO MARKET SIZE, BY PAIN MANAGEMENT, 2018-2030 (USD MILLION)
  • TABLE 163. INDONESIA IN VIVO CRO MARKET SIZE, BY SOLID TUMOR, 2018-2030 (USD MILLION)
  • TABLE 164. JAPAN IN VIVO CRO MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 165. JAPAN IN VIVO CRO MARKET SIZE, BY RODENT, 2018-2030 (USD MILLION)
  • TABLE 166. JAPAN IN VIVO CRO MARKET SIZE, BY GLP TYPE, 2018-2030 (USD MILLION)
  • TABLE 167. JAPAN IN VIVO CRO MARKET SIZE, BY GLP TOXICOLOGY, 2018-2030 (USD MILLION)
  • TABLE 168. JAPAN IN VIVO CRO MARKET SIZE, BY NON-GLP, 2018-2030 (USD MILLION)
  • TABLE 169. JAPAN IN VIVO CRO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 170. JAPAN IN VIVO CRO MARKET SIZE, BY AUTOIMMUNE/INFLAMMATION CONDITIONS, 2018-2030 (USD MILLION)
  • TABLE 171. JAPAN IN VIVO CRO MARKET SIZE, BY CNS CONDITIONS, 2018-2030 (USD MILLION)
  • TABLE 172. JAPAN IN VIVO CRO MARKET SIZE, BY PAIN MANAGEMENT, 2018-2030 (USD MILLION)
  • TABLE 173. JAPAN IN VIVO CRO MARKET SIZE, BY SOLID TUMOR, 2018-2030 (USD MILLION)
  • TABLE 174. MALAYSIA IN VIVO CRO MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 175. MALAYSIA IN VIVO CRO MARKET SIZE, BY RODENT, 2018-2030 (USD MILLION)
  • TABLE 176. MALAYSIA IN VIVO CRO MARKET SIZE, BY GLP TYPE, 2018-2030 (USD MILLION)
  • TABLE 177. MALAYSIA IN VIVO CRO MARKET SIZE, BY GLP TOXICOLOGY, 2018-2030 (USD MILLION)
  • TABLE 178. MALAYSIA IN VIVO CRO MARKET SIZE, BY NON-GLP, 2018-2030 (USD MILLION)
  • TABLE 179. MALAYSIA IN VIVO CRO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 180. MALAYSIA IN VIVO CRO MARKET SIZE, BY AUTOIMMUNE/INFLAMMATION CONDITIONS, 2018-2030 (USD MILLION)
  • TABLE 181. MALAYSIA IN VIVO CRO MARKET SIZE, BY CNS CONDITIONS, 2018-2030 (USD MILLION)
  • TABLE 182. MALAYSIA IN VIVO CRO MARKET SIZE, BY PAIN MANAGEMENT, 2018-2030 (USD MILLION)
  • TABLE 183. MALAYSIA IN VIVO CRO MARKET SIZE, BY SOLID TUMOR, 2018-2030 (USD MILLION)
  • TABLE 184. PHILIPPINES IN VIVO CRO MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 185. PHILIPPINES IN VIVO CRO MARKET SIZE, BY RODENT, 2018-2030 (USD MILLION)
  • TABLE 186. PHILIPPINES IN VIVO CRO MARKET SIZE, BY GLP TYPE, 2018-2030 (USD MILLION)
  • TABLE 187. PHILIPPINES IN VIVO CRO MARKET SIZE, BY GLP TOXICOLOGY, 2018-2030 (USD MILLION)
  • TABLE 188. PHILIPPINES IN VIVO CRO MARKET SIZE, BY NON-GLP, 2018-2030 (USD MILLION)
  • TABLE 189. PHILIPPINES IN VIVO CRO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 190. PHILIPPINES IN VIVO CRO MARKET SIZE, BY AUTOIMMUNE/INFLAMMATION CONDITIONS, 2018-2030 (USD MILLION)
  • TABLE 191. PHILIPPINES IN VIVO CRO MARKET SIZE, BY CNS CONDITIONS, 2018-2030 (USD MILLION)
  • TABLE 192. PHILIPPINES IN VIVO CRO MARKET SIZE, BY PAIN MANAGEMENT, 2018-2030 (USD MILLION)
  • TABLE 193. PHILIPPINES IN VIVO CRO MARKET SIZE, BY SOLID TUMOR, 2018-2030 (USD MILLION)
  • TABLE 194. SINGAPORE IN VIVO CRO MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 195. SINGAPORE IN VIVO CRO MARKET SIZE, BY RODENT, 2018-2030 (USD MILLION)
  • TABLE 196. SINGAPORE IN VIVO CRO MARKET SIZE, BY GLP TYPE, 2018-2030 (USD MILLION)
  • TABLE 197. SINGAPORE IN VIVO CRO MARKET SIZE, BY GLP TOXICOLOGY, 2018-2030 (USD MILLION)
  • TABLE 198. SINGAPORE IN VIVO CRO MARKET SIZE, BY NON-GLP, 2018-2030 (USD MILLION)
  • TABLE 199. SINGAPORE IN VIVO CRO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 200. SINGAPORE IN VIVO CRO MARKET SIZE, BY AUTOIMMUNE/INFLAMMATION CONDITIONS, 2018-2030 (USD MILLION)
  • TABLE 201. SINGAPORE IN VIVO CRO MARKET SIZE, BY CNS CONDITIONS, 2018-2030 (USD MILLION)
  • TABLE 202. SINGAPORE IN VIVO CRO MARKET SIZE, BY PAIN MANAGEMENT, 2018-2030 (USD MILLION)
  • TABLE 203. SINGAPORE IN VIVO CRO MARKET SIZE, BY SOLID TUMOR, 2018-2030 (USD MILLION)
  • TABLE 204. SOUTH KOREA IN VIVO CRO MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 205. SOUTH KOREA IN VIVO CRO MARKET SIZE, BY RODENT, 2018-2030 (USD MILLION)
  • TABLE 206. SOUTH KOREA IN VIVO CRO MARKET SIZE, BY GLP TYPE, 2018-2030 (USD MILLION)
  • TABLE 207. SOUTH KOREA IN VIVO CRO MARKET SIZE, BY GLP TOXICOLOGY, 2018-2030 (USD MILLION)
  • TABLE 208. SOUTH KOREA IN VIVO CRO MARKET SIZE, BY NON-GLP, 2018-2030 (USD MILLION)
  • TABLE 209. SOUTH KOREA IN VIVO CRO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 210. SOUTH KOREA IN VIVO CRO MARKET SIZE, BY AUTOIMMUNE/INFLAMMATION CONDITIONS, 2018-2030 (USD MILLION)
  • TABLE 211. SOUTH KOREA IN VIVO CRO MARKET SIZE, BY CNS CONDITIONS, 2018-2030 (USD MILLION)
  • TABLE 212. SOUTH KOREA IN VIVO CRO MARKET SIZE, BY PAIN MANAGEMENT, 2018-2030 (USD MILLION)
  • TABLE 213. SOUTH KOREA IN VIVO CRO MARKET SIZE, BY SOLID TUMOR, 2018-2030 (USD MILLION)
  • TABLE 214. TAIWAN IN VIVO CRO MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 215. TAIWAN IN VIVO CRO MARKET SIZE, BY RODENT, 2018-2030 (USD MILLION)
  • TABLE 216. TAIWAN IN VIVO CRO MARKET SIZE, BY GLP TYPE, 2018-2030 (USD MILLION)
  • TABLE 217. TAIWAN IN VIVO CRO MARKET SIZE, BY GLP TOXICOLOGY, 2018-2030 (USD MILLION)
  • TABLE 218. TAIWAN IN VIVO CRO MARKET SIZE, BY NON-GLP, 2018-2030 (USD MILLION)
  • TABLE 219. TAIWAN IN VIVO CRO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 220. TAIWAN IN VIVO CRO MARKET SIZE, BY AUTOIMMUNE/INFLAMMATION CONDITIONS, 2018-2030 (USD MILLION)
  • TABLE 221. TAIWAN IN VIVO CRO MARKET SIZE, BY CNS CONDITIONS, 2018-2030 (USD MILLION)
  • TABLE 222. TAIWAN IN VIVO CRO MARKET SIZE, BY PAIN MANAGEMENT, 2018-2030 (USD MILLION)
  • TABLE 223. TAIWAN IN VIVO CRO MARKET SIZE, BY SOLID TUMOR, 2018-2030 (USD MILLION)
  • TABLE 224. THAILAND IN VIVO CRO MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 225. THAILAND IN VIVO CRO MARKET SIZE, BY RODENT, 2018-2030 (USD MILLION)
  • TABLE 226. THAILAND IN VIVO CRO MARKET SIZE, BY GLP TYPE, 2018-2030 (USD MILLION)
  • TABLE 227. THAILAND IN VIVO CRO MARKET SIZE, BY GLP TOXICOLOGY, 2018-2030 (USD MILLION)
  • TABLE 228. THAILAND IN VIVO CRO MARKET SIZE, BY NON-GLP, 2018-2030 (USD MILLION)
  • TABLE 229. THAILAND IN VIVO CRO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 230. THAILAND IN VIVO CRO MARKET SIZE, BY AUTOIMMUNE/INFLAMMATION CONDITIONS, 2018-2030 (USD MILLION)
  • TABLE 231. THAILAND IN VIVO CRO MARKET SIZE, BY CNS CONDITIONS, 2018-2030 (USD MILLION)
  • TABLE 232. THAILAND IN VIVO CRO MARKET SIZE, BY PAIN MANAGEMENT, 2018-2030 (USD MILLION)
  • TABLE 233. THAILAND IN VIVO CRO MARKET SIZE, BY SOLID TUMOR, 2018-2030 (USD MILLION)
  • TABLE 234. VIETNAM IN VIVO CRO MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 235. VIETNAM IN VIVO CRO MARKET SIZE, BY RODENT, 2018-2030 (USD MILLION)
  • TABLE 236. VIETNAM IN VIVO CRO MARKET SIZE, BY GLP TYPE, 2018-2030 (USD MILLION)
  • TABLE 237. VIETNAM IN VIVO CRO MARKET SIZE, BY GLP TOXICOLOGY, 2018-2030 (USD MILLION)
  • TABLE 238. VIETNAM IN VIVO CRO MARKET SIZE, BY NON-GLP, 2018-2030 (USD MILLION)
  • TABLE 239. VIETNAM IN VIVO CRO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 240. VIETNAM IN VIVO CRO MARKET SIZE, BY AUTOIMMUNE/INFLAMMATION CONDITIONS, 2018-2030 (USD MILLION)
  • TABLE 241. VIETNAM IN VIVO CRO MARKET SIZE, BY CNS CONDITIONS, 2018-2030 (USD MILLION)
  • TABLE 242. VIETNAM IN VIVO CRO MARKET SIZE, BY PAIN MANAGEMENT, 2018-2030 (USD MILLION)
  • TABLE 243. VIETNAM IN VIVO CRO MARKET SIZE, BY SOLID TUMOR, 2018-2030 (USD MILLION)
  • TABLE 244. EUROPE, MIDDLE EAST & AFRICA IN VIVO CRO MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 245. EUROPE, MIDDLE EAST & AFRICA IN VIVO CRO MARKET SIZE, BY RODENT, 2018-2030 (USD MILLION)
  • TABLE 246. EUROPE, MIDDLE EAST & AFRICA IN VIVO CRO MARKET SIZE, BY GLP TYPE, 2018-2030 (USD MILLION)
  • TABLE 247. EUROPE, MIDDLE EAST & AFRICA IN VIVO CRO MARKET SIZE, BY GLP TOXICOLOGY, 2018-2030 (USD MILLION)
  • TABLE 248. EUROPE, MIDDLE EAST & AFRICA IN VIVO CRO MARKET SIZE, BY NON-GLP, 2018-2030 (USD MILLION)
  • TABLE 249. EUROPE, MIDDLE EAST & AFRICA IN VIVO CRO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 250. EUROPE, MIDDLE EAST & AFRICA IN VIVO CRO MARKET SIZE, BY AUTOIMMUNE/INFLAMMATION CONDITIONS, 2018-2030 (USD MILLION)
  • TABLE 251. EUROPE, MIDDLE EAST & AFRICA IN VIVO CRO MARKET SIZE, BY CNS CONDITIONS, 2018-2030 (USD MILLION)
  • TABLE 252. EUROPE, MIDDLE EAST & AFRICA IN VIVO CRO MARKET SIZE, BY PAIN MANAGEMENT, 2018-2030 (USD MILLION)
  • TABLE 253. EUROPE, MIDDLE EAST & AFRICA IN VIVO CRO MARKET SIZE, BY SOLID TUMOR, 2018-2030 (USD MILLION)
  • TABLE 254. EUROPE, MIDDLE EAST & AFRICA IN VIVO CRO MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 255. DENMARK IN VIVO CRO MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 256. DENMARK IN VIVO CRO MARKET SIZE, BY RODENT, 2018-2030 (USD MILLION)
  • TABLE 257. DENMARK IN VIVO CRO MARKET SIZE, BY GLP TYPE, 2018-2030 (USD MILLION)
  • TABLE 258. DENMARK IN VIVO CRO MARKET SIZE, BY GLP TOXICOLOGY, 2018-2030 (USD MILLION)
  • TABLE 259. DENMARK IN VIVO CRO MARKET SIZE, BY NON-GLP, 2018-2030 (USD MILLION)
  • TABLE 260. DENMARK IN VIVO CRO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 261. DENMARK IN VIVO CRO MARKET SIZE, BY AUTOIMMUNE/INFLAMMATION CONDITIONS, 2018-2030 (USD MILLION)
  • TABLE 262. DENMARK IN VIVO CRO MARKET SIZE, BY CNS CONDITIONS, 2018-2030 (USD MILLION)
  • TABLE 263. DENMARK IN VIVO CRO MARKET SIZE, BY PAIN MANAGEMENT, 2018-2030 (USD MILLION)
  • TABLE 264. DENMARK IN VIVO CRO MARKET SIZE, BY SOLID TUMOR, 2018-2030 (USD MILLION)
  • TABLE 265. EGYPT IN VIVO CRO MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 266. EGYPT IN VIVO CRO MARKET SIZE, BY RODENT, 2018-2030 (USD MILLION)
  • TABLE 267. EGYPT IN VIVO CRO MARKET SIZE, BY GLP TYPE, 2018-2030 (USD MILLION)
  • TABLE 268. EGYPT IN VIVO CRO MARKET SIZE, BY GLP TOXICOLOGY, 2018-2030 (USD MILLION)
  • TABLE 269. EGYPT IN VIVO CRO MARKET SIZE, BY NON-GLP, 2018-2030 (USD MILLION)
  • TABLE 270. EGYPT IN VIVO CRO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 271. EGYPT IN VIVO CRO MARKET SIZE, BY AUTOIMMUNE/INFLAMMATION CONDITIONS, 2018-2030 (USD MILLION)
  • TABLE 272. EGYPT IN VIVO CRO MARKET SIZE, BY CNS CONDITIONS, 2018-2030 (USD MILLION)
  • TABLE 273. EGYPT IN VIVO CRO MARKET SIZE, BY PAIN MANAGEMENT, 2018-2030 (USD MILLION)
  • TABLE 274. EGYPT IN VIVO CRO MARKET SIZE, BY SOLID TUMOR, 2018-2030 (USD MILLION)
  • TABLE 275. FINLAND IN VIVO CRO MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 276. FINLAND IN VIVO CRO MARKET SIZE, BY RODENT, 2018-2030 (USD MILLION)
  • TABLE 277. FINLAND IN VIVO CRO MARKET SIZE, BY GLP TYPE, 2018-2030 (USD MILLION)
  • TABLE 278. FINLAND IN VIVO CRO MARKET SIZE, BY GLP TOXICOLOGY, 2018-2030 (USD MILLION)
  • TABLE 279. FINLAND IN VIVO CRO MARKET SIZE, BY NON-GLP, 2018-2030 (USD MILLION)
  • TABLE 280. FINLAND IN VIVO CRO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 281. FINLAND IN VIVO CRO MARKET SIZE, BY AUTOIMMUNE/INFLAMMATION CONDITIONS, 2018-2030 (USD MILLION)
  • TABLE 282. FINLAND IN VIVO CRO MARKET SIZE, BY CNS CONDITIONS, 2018-2030 (USD MILLION)
  • TABLE 283. FINLAND IN VIVO CRO MARKET SIZE, BY PAIN MANAGEMENT, 2018-2030 (USD MILLION)
  • TABLE 284. FINLAND IN VIVO CRO MARKET SIZE, BY SOLID TUMOR, 2018-2030 (USD MILLION)
  • TABLE 285. FRANCE IN VIVO CRO MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 286. FRANCE IN VIVO CRO MARKET SIZE, BY RODENT, 2018-2030 (USD MILLION)
  • TABLE 287. FRANCE IN VIVO CRO MARKET SIZE, BY GLP TYPE, 2018-2030 (USD MILLION)
  • TABLE 288. FRANCE IN VIVO CRO MARKET SIZE, BY GLP TOXICOLOGY, 2018-2030 (USD MILLION)
  • TABLE 289. FRANCE IN VIVO CRO MARKET SIZE, BY NON-GLP, 2018-2030 (USD MILLION)
  • TABLE 290. FRANCE IN VIVO CRO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 291. FRANCE IN VIVO CRO MARKET SIZE, BY AUTOIMMUNE/INFLAMMATION CONDITIONS, 2018-2030 (USD MILLION)
  • TABLE 292. FRANCE IN VIVO CRO MARKET SIZE, BY CNS CONDITIONS, 2018-2030 (USD MILLION)
  • TABLE 293. FRANCE IN VIVO CRO MARKET SIZE, BY PAIN MANAGEMENT, 2018-2030 (USD MILLION)
  • TABLE 294. FRANCE IN VIVO CRO MARKET SIZE, BY SOLID TUMOR, 2018-2030 (USD MILLION)
  • TABLE 295. GERMANY IN VIVO CRO MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 296. GERMANY IN VIVO CRO MARKET SIZE, BY RODENT, 2018-2030 (USD MILLION)
  • TABLE 297. GERMANY IN VIVO CRO MARKET SIZE, BY GLP TYPE, 2018-2030 (USD MILLION)
  • TABLE 298. GERMANY IN VIVO CRO MARKET SIZE, BY GLP TOXICOLOGY, 2018-2030 (USD MILLION)
  • TABLE 299. GERMANY IN VIVO CRO MARKET SIZE, BY NON-GLP, 2018-2030 (USD MILLION)
  • TABLE 300. GERMANY IN VIVO CRO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 301. GERMANY IN VIVO CRO MARKET SIZE, BY AUTOIMMUNE/INFLAMMATION CONDITIONS, 2018-2030 (USD MILLION)
  • TABLE 302. GERMANY IN VIVO CRO MARKET SIZE, BY CNS CONDITIONS, 2018-2030 (USD MILLION)
  • TABLE 303. GERMANY IN VIVO CRO MARKET SIZE, BY PAIN MANAGEMENT, 2018-2030 (USD MILLION)
  • TABLE 304. GERMANY IN VIVO CRO MARKET SIZE, BY SOLID TUMOR, 2018-2030 (USD MILLION)
  • TABLE 305. ISRAEL IN VIVO CRO MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 306. ISRAEL IN VIVO CRO MARKET SIZE, BY RODENT, 2018-2030 (USD MILLION)
  • TABLE 307. ISRAEL IN VIVO CRO MARKET SIZE, BY GLP TYPE, 2018-2030 (USD MILLION)
  • TABLE 308. ISRAEL IN VIVO CRO MARKET SIZE, BY GLP TOXICOLOGY, 2018-2030 (USD MILLION)
  • TABLE 309. ISRAEL IN VIVO CRO MARKET SIZE, BY NON-GLP, 2018-2030 (USD MILLION)
  • TABLE 310. ISRAEL IN VIVO CRO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 311. ISRAEL IN VIVO CRO MARKET SIZE, BY AUTOIMMUNE/INFLAMMATION CONDITIONS, 2018-2030 (USD MILLION)
  • TABLE 312. ISRAEL IN VIVO CRO MARKET SIZE, BY CNS CONDITIONS, 2018-2030 (USD MILLION)
  • TABLE 313. ISRAEL IN VIVO CRO MARKET SIZE, BY PAIN MANAGEMENT, 2018-2030 (USD MILLION)
  • TABLE 314. ISRAEL IN VIVO CRO MARKET SIZE, BY SOLID TUMOR, 2018-2030 (USD MILLION)
  • TABLE 315. ITALY IN VIVO CRO MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 316. ITALY IN VIVO CRO MARKET SIZE, BY RODENT, 2018-2030 (USD MILLION)
  • TABLE 317. ITALY IN VIVO CRO MARKET SIZE, BY GLP TYPE, 2018-2030 (USD MILLION)
  • TABLE 318. ITALY IN VIVO CRO MARKET SIZE, BY GLP TOXICOLOGY, 2018-2030 (USD MILLION)
  • TABLE 319. ITALY IN VIVO CRO MARKET SIZE, BY NON-GLP, 2018-2030 (USD MILLION)
  • TABLE 320. ITALY IN VIVO CRO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 321. ITALY IN VIVO CRO MARKET SIZE, BY AUTOIMMUNE/INFLAMMATION CONDITIONS, 2018-2030 (USD MILLION)
  • TABLE 322. ITALY IN VIVO CRO MARKET SIZE, BY CNS CONDITIONS, 2018-2030 (USD MILLION)
  • TABLE 323. ITALY IN VIVO CRO MARKET SIZE, BY PAIN MANAGEMENT, 2018-2030 (USD MILLION)
  • TABLE 324. ITALY IN VIVO CRO MARKET SIZE, BY SOLID TUMOR, 2018-2030 (USD MILLION)
  • TABLE 325. NETHERLANDS IN VIVO CRO MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 326. NETHERLANDS IN VIVO CRO MARKET SIZE, BY RODENT, 2018-2030 (USD MILLION)
  • TABLE 327. NETHERLANDS IN VIVO CRO MARKET SIZE, BY GLP TYPE, 2018-2030 (USD MILLION)
  • TABLE 328. NETHERLANDS IN VIVO CRO MARKET SIZE, BY GLP TOXICOLOGY, 2018-2030 (USD MILLION)
  • TABLE 329. NETHERLANDS IN VIVO CRO MARKET SIZE, BY NON-GLP, 2018-2030 (USD MILLION)
  • TABLE 330. NETHERLANDS IN VIVO CRO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 331. NETHERLANDS IN VIVO CRO MARKET SIZE, BY AUTOIMMUNE/INFLAMMATION CONDITIONS, 2018-2030 (USD MILLION)
  • TABLE 332. NETHERLANDS IN VIVO CRO MARKET SIZE, BY CNS CONDITIONS, 2018-2030 (USD MILLION)
  • TABLE 333. NETHERLANDS IN VIVO CRO MARKET SIZE, BY PAIN MANAGEMENT, 2018-2030 (USD MILLION)
  • TABLE 334. NETHERLANDS IN VIVO CRO MARKET SIZE, BY SOLID TUMOR, 2018-2030 (USD MILLION)
  • TABLE 335. NIGERIA IN VIVO CRO MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 336. NIGERIA IN VIVO CRO MARKET SIZE, BY RODENT, 2018-2030 (USD MILLION)
  • TABLE 337. NIGERIA IN VIVO CRO MARKET SIZE, BY GLP TYPE, 2018-2030 (USD MILLION)
  • TABLE 338. NIGERIA IN VIVO CRO MARKET SIZE, BY GLP TOXICOLOGY, 2018-2030 (USD MILLION)
  • TABLE 339. NIGERIA IN VIVO CRO MARKET SIZE, BY NON-GLP, 2018-2030 (USD MILLION)
  • TABLE 340. NIGERIA IN VIVO CRO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 341. NIGERIA IN VIVO CRO MARKET SIZE, BY AUTOIMMUNE/INFLAMMATION CONDITIONS, 2018-2030 (USD MILLION)
  • TABLE 342. NIGERIA IN VIVO CRO MARKET SIZE, BY CNS CONDITIONS, 2018-2030 (USD MILLION)
  • TABLE 343. NIGERIA IN VIVO CRO MARKET SIZE, BY PAIN MANAGEMENT, 2018-2030 (USD MILLION)
  • TABLE 344. NIGERIA IN VIVO CRO MARKET SIZE, BY SOLID TUMOR, 2018-2030 (USD MILLION)
  • TABLE 345. NORWAY IN VIVO CRO MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 346. NORWAY IN VIVO CRO MARKET SIZE, BY RODENT, 2018-2030 (USD MILLION)
  • TABLE 347. NORWAY IN VIVO CRO MARKET SIZE, BY GLP TYPE, 2018-2030 (USD MILLION)
  • TABLE 348. NORWAY IN VIVO CRO MARKET SIZE, BY GLP TOXICOLOGY, 2018-2030 (USD MILLION)
  • TABLE 349. NORWAY IN VIVO CRO MARKET SIZE, BY NON-GLP, 2018-2030 (USD MILLION)
  • TABLE 350. NORWAY IN VIVO CRO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 351. NORWAY IN VIVO CRO MARKET SIZE, BY AUTOIMMUNE/INFLAMMATION CONDITIONS, 2018-2030 (USD MILLION)
  • TABLE 352. NORWAY IN VIVO CRO MARKET SIZE, BY CNS CONDITIONS, 2018-2030 (USD MILLION)
  • TABLE 353. NORWAY IN VIVO CRO MARKET SIZE, BY PAIN MANAGEMENT, 2018-2030 (USD MILLION)
  • TABLE 354. NORWAY IN VIVO CRO MARKET SIZE, BY SOLID TUMOR, 2018-2030 (USD MILLION)
  • TABLE 355. POLAND IN VIVO CRO MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 356. POLAND IN VIVO CRO MARKET SIZE, BY RODENT, 2018-2030 (USD MILLION)
  • TABLE 357. POLAND IN VIVO CRO MARKET SIZE, BY GLP TYPE, 2018-2030 (USD MILLION)
  • TABLE 358. POLAND IN VIVO CRO MARKET SIZE, BY GLP TOXICOLOGY, 2018-2030 (USD MILLION)
  • TABLE 359. POLAND IN VIVO CRO MARKET SIZE, BY NON-GLP, 2018-2030 (USD MILLION)
  • TABLE 360. POLAND IN VIVO CRO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 361. POLAND IN VIVO CRO MARKET SIZE, BY AUTOIMMUNE/INFLAMMATION CONDITIONS, 2018-2030 (USD MILLION)
  • TABLE 362. POLAND IN VIVO CRO MARKET SIZE, BY CNS CONDITIONS, 2018-2030 (USD MILLION)
  • TABLE 363. POLAND IN VIVO CRO MARKET SIZE, BY PAIN MANAGEMENT, 2018-2030 (USD MILLION)
  • TABLE 364. POLAND IN VIVO CRO MARKET SIZE, BY SOLID TUMOR, 2018-2030 (USD MILLION)
  • TABLE 365. QATAR IN VIVO CRO MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 366. QATAR IN VIVO CRO MARKET SIZE, BY RODENT, 2018-2030 (USD MILLION)
  • TABLE 367. QATAR IN VIVO CRO MARKET SIZE, BY GLP TYPE, 2018-2030 (USD MILLION)
  • TABLE 368. QATAR IN VIVO CRO MARKET SIZE, BY GLP TOXICOLOGY, 2018-2030 (USD MILLION)
  • TABLE 369. QATAR IN VIVO CRO MARKET SIZE, BY NON-GLP, 2018-2030 (USD MILLION)
  • TABLE 370. QATAR IN VIVO CRO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 371. QATAR IN VIVO CRO MARKET SIZE, BY AUTOIMMUNE/INFLAMMATION CONDITIONS, 2018-2030 (USD MILLION)
  • TABLE 372. QATAR IN VIVO CRO MARKET SIZE, BY CNS CONDITIONS, 2018-2030 (USD MILLION)
  • TABLE 373. QATAR IN VIVO CRO MARKET SIZE, BY PAIN MANAGEMENT, 2018-2030 (USD MILLION)
  • TABLE 374. QATAR IN VIVO CRO MARKET SIZE, BY SOLID TUMOR, 2018-2030 (USD MILLION)
  • TABLE 375. RUSSIA IN VIVO CRO MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 376. RUSSIA IN VIVO CRO MARKET SIZE, BY RODENT, 2018-2030 (USD MILLION)
  • TABLE 377. RUSSIA IN VIVO CRO MARKET SIZE, BY GLP TYPE, 2018-2030 (USD MILLION)
  • TABLE 378. RUSSIA IN VIVO CRO MARKET SIZE, BY GLP TOXICOLOGY, 2018-2030 (USD MILLION)
  • TABLE 379. RUSSIA IN VIVO CRO MARKET SIZE, BY NON-GLP, 2018-2030 (USD MILLION)

TA